AbolerIS Pharma

Foundation date

28/11/2019

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance and preserves useful immune responses in inflammatory, autoimmune and degenerative diseases.

Anti-CD45RC monoclonal antibody to deplete effector T cells and preserve regulatory and memory T cells.

IL-34 cytokine to induce tolerogenic macrophages/DCs and regulatory T cells.

Founded by a team with a long cutting-edge translational expertise in regulatory T cells and mechanisms of tolerance.

Upcoming events

Latest news

  • Company growth prompts Connected-Pathology relocation to larger laboratory facilities to accommodate increase in study capacity

    23 hours ago

  • Japan welcomes companies, startups and knowledge institutions from Flanders

    Friday December 2nd 2022

  • FIT stimulates market diversification with renewed subsidy

    Thursday December 1st 2022